Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap

Authors, Journal, Affiliations, Type, DOI

• Authors: Peter A. Noseworthy (Chair), Elizabeth S. Kaufman, Lin Y. Chen, Mina K. Chung, Mitchell S.V. Elkind, José A. Joglar, Miguel A. Leal, Pamela J. McCabe, Sean D. Pokorney, Xiaoxi Yao
• Journal: Circulation, 2019;140:e944–e963
• Affiliations: Mayo Clinic, MetroHealth/Case Western, University of Minnesota, Cleveland Clinic, Columbia University, UT Southwestern, University of Wisconsin, Duke University
• Type: AHA Scientific Statement (Consensus)
• DOI: https://doi.org/10.1161/CIR.0000000000000740

Overview

This AHA scientific statement synthesizes evidence on subclinical atrial fibrillation (SCAF) — asymptomatic AF detected by cardiac implantable electronic devices (CIEDs) or wearable monitors, not previously identified on standard ECG or ambulatory monitoring. SCAF is common in CIED populations (10–55% depending on cohort and detection thresholds) and carries a 2.4-fold increased stroke risk. The document identifies the dose-dependent relationship between AF episode duration and stroke risk, with episodes >24 hours driving the highest burden. As of 2019, the optimal anticoagulation threshold was undefined; two ongoing RCTs (ARTESiA, NOAH) were expected to clarify management.

Keywords

AHA Scientific Statements, ambulatory monitoring, atrial fibrillation, cardiac arrhythmia, cardiac pacing, cerebrovascular stroke, pacemaker

Key Takeaways

Definitions

• SCAF (Subclinical Atrial Fibrillation): Asymptomatic episodes of AF detected and confirmed by intracardiac electrograms or wearable monitors, not previously detected by ECG or ambulatory monitoring.
• AHRE (Atrial High-Rate Episodes): Device-detected atrial events meeting programmed atrial high-rate criteria (typically 175–220 bpm); includes both true AT/AF and false positives (17.3% false-positive rate in ASSERT).
• SCAT (Subclinical Atrial Tachyarrhythmia): Broader term including AF, atrial flutter, and AT detected by device.
• Episode duration thresholds used to define SCAF vary widely across studies (20 seconds to >24 hours); no consensus definition as of 2019.

Detection and Diagnosis

• Spectrum of devices: wearables (adhesive patches, wristbands, smartwatches with PPG/ECG) → external cardiac monitors → implantable cardiac monitors (ICMs/ILRs) → permanent CIEDs with atrial leads.
• CIEDs with atrial leads provide intracardiac electrograms enabling highest-confidence AF confirmation.
• Subcutaneous ICMs (loop recorders) detect AF via R-R irregularity algorithms — require electrogram review to exclude false positives.
• Wearable photoplethysmography (PPG) detects irregular rhythm but requires ECG confirmation before acting on findings.
• Key wearable performance data: ZIO patch concordance r=0.99 with pacemaker AF burden; MCOT 100% sensitivity/specificity for AF >30s; Apple Watch ECG c-statistic 0.97.

Prevalence of SCAF

• CIED-detected AHRE prevalence: 10% at 3 months (ASSERT) rising to 34.7% over 2.5 years; 50% in MOST pacemaker population; 49.6% in TRENDS (PPM group) over 1.4 years.
• Longer monitoring duration and higher-risk populations yield progressively higher detection rates.
• ESUS population: EMBRACE trial (30-day monitor) 16.1% vs. 3.2% for 24-h Holter; CRYSTAL AF (ICM) 9% at 6 months, 12% at 12 months, 30% at 36 months; meta-analysis (32 trials) 11.5%.
• Overall AF detection yield after sequential cardiac monitoring in meta-analysis of 50 studies: 23.7%.

Predictors of SCAF

• Common predictors: older age, history of heart failure, sinus node dysfunction, increased left atrial size, lower resting HR.
• ASSERT predictors: sinus node dysfunction, lower resting heart rate; patients with SCAF were less likely to have DM or prior MI.
• ESUS predictors (EMBRACE): high atrial premature beat count on baseline Holter (≥500 APBs/24h → >25% AF detection rate); runs of AT, age, and LA enlargement not independently predictive.
• CRYSTAL AF predictors: older age (HR 1.9/decade) and longer PR interval.

Relationship with Stroke

• Meta-analysis (7 studies, n=15,353): SCAF associated with 2.4-fold (95% CI 1.8–3.3) stroke risk increase; absolute annual rate 1.89 per 100 person-years.
• Dose-dependent relationship: stroke risk increases with AF duration; episodes >24 hours drive the bulk of events (ASSERT Figure 4); short episodes (<15–20 seconds) not associated with clinical events.
• ASSERT subanalysis: stroke risk only significant for episodes >17.72 hours.
• CHA₂DS₂ score modifies the relationship: CHADS₂ ≥2 → even brief AF episodes (>5 min) increase risk (Botto 2009).
• Critical debate: in ASSERT, many strokes were not temporally related to SCAF episodes → AF as risk marker vs. direct cause (Figure 6, 7).

SCAF and ESUS

• 24% (95% CI 17–31) of ESUS patients detected to have SCAF during follow-up across 50 studies.
• CRYSTAL AF: most AF was asymptomatic; 97% received anticoagulation after AF detection; median AF duration was 4.3 min/day.

Progression to Clinical AF

• SCAF predicts 5.6–5.9× higher hazard of clinical AF (ASSERT 5.6×, MOST 5.9×, meta-analysis 5.7×).
• Among ASSERT patients with 6 min–24 h SCAF, 16% progressed to clinical AF or SCAF >24 h over 2-year follow-up.
• Predictors of progression: older age, higher BMI, and longer initial SCAF episodes.
• Pooled analysis (TRENDS, PANORAMA, SOS AF): longer initial SCAF episodes → faster progression to AF ≥23 hours.

SCAF and Heart Failure

• AF and HF are bidirectionally linked; AF prevalence in HF ranges 13–50%.
• Device-detected AF lasting ≥24 hours was associated with HF hospitalization in ASSERT.
• Common risk factors (age, hypertension, DM, obesity, structural heart disease) underlie both conditions.

Management (as of 2019)

• No established evidence-based threshold for initiating OAC in SCAF.
• Practice variation documented: VA registry (n=10,212 CIED patients) — OAC initiation within 90 days ranged 13% (SCAF ≥6 min) to 27% (SCAF >24 h); average time to OAC >30 days for all AF burdens.
• Proposed approach: combine CHA₂DS₂-VASc score with SCAF duration/burden (Figure 9):
  • Low risk or very brief AHREs → defer anticoagulation.
  • Intermediate risk + AHREs 6 min–24 h → uncertain; study in ARTESiA/NOAH.
  • High risk + longer episodes → consider anticoagulation.
• After stroke, any SCAF duration is generally considered a reason to anticoagulate.
• "Pill in the pocket" anticoagulation guided by continuous monitoring: exploratory concept only (REACT.COM, IMPACT).
• Shared decision-making and pragmatic trials recommended given data uncertainty.

Limitations of the Document

• 2019 data: ARTESiA and NOAH results were not yet available; management guidance was expert opinion.
• No consensus on AHRE rate threshold (175–220 bpm range across studies) or duration threshold; makes cross-study comparison difficult.
• Studies predominantly enrolled patients with CIEDs — extrapolation to wearable-detected SCAF was uncertain.
• False-positive AHRE rate (~17%) requires electrogram review before clinical action.
• CHA₂DS₂-VASc performance in SCAF populations was not well validated.
• Most risk factors for stroke overlap with bleeding risk factors, complicating net clinical benefit assessment.

Key Concepts Mentioned

• concepts/Subclinical-AF — the primary subject of this source
• concepts/CHA2DS2-VA — stroke risk stratification tool applied to SCAF management
• concepts/AF-Staging — SCAF as pre-clinical AF stage

Key Entities Mentioned

• entities/Atrial-Fibrillation — clinical AF as the comparator and downstream outcome
• entities/Heart-Failure — bidirectional SCAF-HF association; SCAF ≥24h predicts HF hospitalisation

Wiki Pages Updated

• wiki/sources/subclinical-af-aha-2019.md — created (this file)
• wiki/concepts/Subclinical-AF.md — created
• wiki/entities/Atrial-Fibrillation.md — updated SCAF section with foundational trial citations
• wiki/wikiindex.md — added Subclinical-AF concept entry
• wiki/sourceindex.md — added this source
• log.md — appended